Back to Search
Start Over
Immunogenicity of a vaccinia virus-based severe acute respiratory syndrome coronavirus 2 vaccine candidate.
- Source :
- Frontiers in Immunology; 7/22/2022, Vol. 13, p1-10, 10p
- Publication Year :
- 2022
-
Abstract
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines provide essential tools for the control of the COVID-19 pandemic. A number of technologies have been employed to develop SARS-CoV-2 vaccines, including the inactivated SARS-CoV-2 particles, mRNA to express viral spike protein, recombinant spike proteins, and viral vectors. Here, we report the use of the vaccinia virus Tiantan strain as a vector to express the SARS-CoV-2 spike protein. When it was used to inoculate mice, robust SARS-CoV-2 spike protein-specific antibody response and T-cell response were detected. Sera from the vaccinated mice showed strong neutralizing activity against the ancestral Wuhan SARS-CoV-2, the variants of concern (VOCs) B.1.351, B.1.617.2, and the emerging B.1.1.529 (omicron). This finding supports the possibility of developing a new type of SARS-CoV-2 vaccine using the vaccinia virus vector. [ABSTRACT FROM AUTHOR]
- Subjects :
- SARS-CoV-2
COVID-19 vaccines
GENETIC vectors
VACCINIA
IMMUNE response
Subjects
Details
- Language :
- English
- ISSN :
- 16643224
- Volume :
- 13
- Database :
- Complementary Index
- Journal :
- Frontiers in Immunology
- Publication Type :
- Academic Journal
- Accession number :
- 158536382
- Full Text :
- https://doi.org/10.3389/fimmu.2022.911164